Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15868789 | 0.85 | MEN1 (0.34) | TP53 | |
| SCHEMBL25584128 | 0.74 | — | — | |
| SCHEMBL12709067 | 0.73 | TBXAS1 (0.50) | — | |
| SCHEMBL18213823 | 0.73 | IDO1 (0.40) | — | |
| SCHEMBL4456152 | 0.72 | — | — | |
| SCHEMBL8893900 | 0.70 | SMN1; SMN2 (0.60) | TP53 | |
| SCHEMBL14578717 | 0.70 | MEN1 (0.32) | TP53 | |
| SCHEMBL24335318 | 0.69 | NPC1 (0.60) | TP53 | |
| SCHEMBL8050553 | 0.68 | ALDH1A1 (0.36) | TP53 | |
| SCHEMBL9824207 | 0.67 | TP53 (0.39) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20170037059-A1 | GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-09 | — | — | US | disclosed |
| EP-2459599-B1 | IN SITU FORMATION OF HYDROXY CHAIN END FUNCTIONAL POLYOLEFINS | UNIV SOUTHERN MISSISSIPPI (US) | 2016-07-20 | — | — | EP | disclosed |
| US-9150672-B2 | In situ formation of hydroxy chain end functional polyolefins | THE UNIVERSITY OF SOUTHERN MISSISSIPPI (US) | 2015-10-06 | — | — | US | disclosed |
| CN-102471398-B | In situ formation of hydroxy chain end functional polyolefins | UNIV SOUTHERN MISSISSIPPI | 2014-01-29 | — | — | CN | disclosed |
| US-20130158206-A1 | IN SITU FORMATION OF HYDROXY CHAIN END FUNCTIONAL POLYOLEFINS | THE UNIVERSITY OF SOUTHERN MISSISSIPPI (US) | 2013-06-20 | — | — | US | disclosed |
| US-8394898-B2 | In situ formation of hydroxy chain end functional polyolefins | THE UNIVERSITY OF SOUTHERN MISSISSIPPI (US) | 2013-03-12 | — | — | US | disclosed |
| EP-2459599-A2 | IN SITU FORMATION OF HYDROXY CHAIN END FUNCTIONAL POLYOLEFINS | The University of Southern Mississippi (US) | 2012-06-06 | — | — | EP | disclosed |
| CN-102471398-A | In situ formation of hydroxyl terminated functional polyolefins | UNIV SOUTHERN MISSISSIPPI | 2012-05-23 | — | — | CN | disclosed |
| US-20110028681-A1 | IN SITU FORMATION OF HYDROXY CHAIN END FUNCTIONAL POLYOLEFINS | THE UNIVERSITY OF SOUTHERN MISSISSIPPI | 2011-02-03 | — | — | US | disclosed |
| WO-2011014665-A2 | IN SITU FORMATION OF HYDROXY CHAIN END FUNCTIONAL POLYOLEFINS | THE UNIVERSITY OF SOUTHERN MISSISSIPPI (US) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | SLC40A1, HAMP, SLC19A1 | TP53 1638/4885 |
| US-20170037059-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | TP53 3289/4885 |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | HAMP, SLC40A1, FANCI | TP53 1806/4885 |
| US-20110028681-A1 | IN SITU FORMATION OF HYDROXY CHAIN END FUNCTIONAL POLYOLEFINS | RXFP3, HCAR3, LPAR3 | TP53 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.